GlassScriptPhysician profile
Heather Becerril
NPI 1306429311
$1,821.03
in general payments reported to CMS, 2019-2025
15 companies · $723 in 2025
The $723 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $270 · 2024: $828 · 2025: $723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,821.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $628.94 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Corcept Therapeutics | $518.90 | 2023-2025 | Korlym |
| Lilly USA, LLC | $201.92 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $187.21 | 2023-2025 | Farxiga |
| Xeris Pharmaceuticals, INC. | $53.49 | 2024 | Recorlev |
| Exeltis, USA INC. | $45.08 | 2024 | Slynd |
| Acella Pharmaceuticals, LLC | $37.77 | 2024-2025 | NP Thyroid 60 |
| Novartis Pharmaceuticals Corporation | $24.88 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.40 | 2025 | |
| Ucb, INC. | $18.91 | 2025 | Bimzelx |
| Shield Therapeutics INC | $18.73 | 2025 | |
| Recordati_rare_diseases_inc. | $18.56 | 2025 | Isturisa |
| Sanofi-Aventis U.S. LLC | $17.65 | 2024 | |
| Astellas Pharma US INC | $14.91 | 2025 | Veozah |
| Dexcom, INC. | $13.68 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Becerril listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.